Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to suppor t the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally.
Company profile
Ticker
MYO
Exchange
Website
CEO
Paul Gudonis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Avanos Medical • Edwards Lifesciences • Invacare • MSA Safety • Align Technology • Surgalign ...
Former names
MYOMO INC
SEC CIK
Corporate docs
Subsidiaries
Myomo Europe GmbH ...
MYO stock data
Latest filings (excl ownership)
8-K
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
30 Jan 23
EFFECT
Notice of effectiveness
17 Jan 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
424B4
Prospectus supplement with pricing info
13 Jan 23
S-1MEF
Registration of additional securities for an S-1
11 Jan 23
S-1/A
IPO registration (amended)
10 Jan 23
8-K
Myomo Announces Initiative to Reduce Cash Burn
10 Jan 23
S-1/A
IPO registration (amended)
10 Jan 23
S-1/A
IPO registration (amended)
4 Jan 23
S-1
IPO registration
7 Dec 22
Transcripts
MYO
Earnings call transcript
2022 Q3
11 Nov 22
MYO
Earnings call transcript
2022 Q2
6 Aug 22
MYO
Earnings call transcript
2022 Q1
11 May 22
MYO
Earnings call transcript
2021 Q4
10 Mar 22
MYO
Earnings call transcript
2021 Q3
11 Nov 21
MYO
Earnings call transcript
2021 Q2
10 Aug 21
MYO
Earnings call transcript
2021 Q1
9 May 21
MYO
Earnings call transcript
2020 Q4
11 Mar 21
MYO
Earnings call transcript
2020 Q3
10 Nov 20
MYO
Earnings call transcript
2020 Q2
10 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.42 mm | 7.42 mm | 7.42 mm | 7.42 mm | 7.42 mm | 7.42 mm |
| Cash burn (monthly) | 938.63 k | 432.23 k | 939.55 k | 931.96 k | 932.91 k | 799.82 k |
| Cash used (since last report) | 3.87 mm | 1.78 mm | 3.88 mm | 3.85 mm | 3.85 mm | 3.30 mm |
| Cash remaining | 3.55 mm | 5.64 mm | 3.54 mm | 3.57 mm | 3.57 mm | 4.12 mm |
| Runway (months of cash) | 3.8 | 13.0 | 3.8 | 3.8 | 3.8 | 5.1 |
Institutional ownership, Q3 2022
44.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 18 |
| Opened positions | 1 |
| Closed positions | 6 |
| Increased positions | 1 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 12.45 mm |
| Total shares | 3.15 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Hirschman Orin | 617.18 k | $4.23 mm |
| AIGH Capital Management | 617.18 k | $999.00 k |
| Rosalind Advisors | 553.29 k | $3.79 mm |
| Must Asset Management | 461.86 k | $750.00 k |
| CVI Investments | 240.64 k | $1.62 mm |
| Vanguard | 211.53 k | $343.00 k |
| Worth Venture Partners | 153.94 k | $249.00 k |
| Bridgeway Capital Management | 140.51 k | $228.00 k |
| Geode Capital Management | 46.61 k | $75.00 k |
| Renaissance Technologies | 40.80 k | $66.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Jan 23 | Gudonis Paul R | Common Stock | Buy | Acquire P | No | No | 0.325 | 307,692 | 100.00 k | 483,345 |
| 17 Jan 23 | Henry David A | Common Stock | Buy | Acquire P | No | No | 0.325 | 76,923 | 25.00 k | 163,527 |
| 17 Jan 23 | Mitchell Micah | Common Stock | Buy | Acquire P | No | No | 0.325 | 15,384 | 5.00 k | 64,815 |
| 4 Jan 23 | Harry Kovelman | Common Stock | Payment of exercise | Dispose F | No | No | 0.49 | 139 | 68.11 | 50,579 |
| 5 Dec 22 | Harry Kovelman | Common Stock | Payment of exercise | Dispose F | No | No | 0.66 | 126 | 83.16 | 50,718 |
News
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
19 Jan 23
Why Myomo Shares Are Diving
12 Jan 23
Myomo Announces Pricing Of $6.5M Upsized Public Offering Of 20M Shares Of Common Stock At A Price Of $0.325/Share
12 Jan 23
KB Home, Bed Bath & Beyond And 3 Stocks To Watch Heading Into Wednesday
11 Jan 23
Looking Into Myomo's Return On Capital Employed
21 Dec 22
Press releases
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
30 Jan 23
Myomo Announces Closing of $6.5 Million Upsized Public Offering
17 Jan 23
Myomo Announces Pricing of $6.5 Million Upsized Public Offering
12 Jan 23
Myomo Announces Initiative to Reduce Cash Burn
10 Jan 23
Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro
7 Dec 22